促肝细胞生长素和CTGF反义寡核苷酸对肾纤维化的改善作用
|
摘要
目的:
观察促肝细胞生长素(pHGF)和结缔组织生长因子(CTGF)反义寡核苷酸(ASODN)对人肾小管上皮细胞HKC上皮-间质细胞转分化,及对大鼠肾间质纤维化的作用。
方法:
细胞实验:用巨噬细胞趋化因子-1和马兜铃酸I联合用药诱导建立HKC上皮-间质细胞转分化模型。分别给与pHGF、CTGF ASODN和(pHGF+CTGF ASODN)联合用药。流式细胞仪检测12h、24h时HKC细胞凋亡率;RT-PCR方法检测α-SMA的mRNA表达水平;细胞免疫组化检测HKC细胞α-SMA、TGF-β_1、FN的蛋白表达水平。
动物实验:48只清洁级Sprague-Dawley(SD)大鼠随机分为假手术空白对照组、手术模型对照组、CTGF错义寡核苷酸对照组(CTGF MSODN)、pHGF组、CTGFASODN组、(pHGF+CTGF ASODN)联合用药组。以上各组造模后给予不同处理,饲养14d,然后处死大鼠。碱水解比色法检测新鲜湿重大鼠肾组织胶原定量;Masson染色观察肾皮质胶原形态学改变;RT-PCR检测大鼠肾组织α-SMA的mRNA表达水平;免疫组化检测大鼠肾肾皮质α-SMA、TGF-β_1、FN蛋白表达水平。
结果:
细胞试验:流式细胞仪检测:24 h模型组细胞凋亡率9.1%,浓度为15、150、1500 ng/ml的pHGF细胞凋亡率为3.3%—4.4%,与模型组比较,有显著性差异,p＜0.01;CTGF ASODN无显著差异,p＞0.05;RT-PCR方法:模型组的α-SMA/GAPDH比值为0.91±0.002,pHGF组、CTGF ASODN组和联合用药组α-SMA/GAPDH比值分别为0.68±0.015、0.61±0.005、0.65±0.010。与模型对照组比较,三者均有统计学意义,p＜0.05。但协同拮抗作用经金正均概率和法分析:Q=0.572,＜0.85,二者为拮抗作用;免疫组化检测:pHGF、CTGF ASODN和联合用药均降低α-SMA、TGF-β_1、FN蛋白水平。
动物试验:碱水解比色法:湿重肾组织胶原含量UUO模型组均值为4.85±0.201μg/mg,pHGF组均值为3.76±0.134μg/mg,CTGF ASODN组均值为3.34±0.306μg/mg,联合用药组为4.06±0.179μg/mg,CTGF MSODN错义寡核苷酸对照组为4.91±0.172。与UUO模型组比较,pHGF组、CTGF ASODN组及联合用药组均有显著性差异,p＜0.01。但协同拮抗作用,经金正均概率和法分析:pHGF和CTGF ASODN两种药物的Q=0.349,＜0.85,二者为拮抗作用;②Masson染色:与UUO模型对照组相比,pHGF、CTGF ASODN及联合用药组的肾脏着色绿染的胶原纤维面积明显减少;③RT-PCR检测:UUO模型组α-SMA/β-actin比值为1.31±0.049,CTGF ASODN组为0.77±0.022,有统计学意义,p＜0.05;④免疫组化:pHGF、CTGF ASODN及二者联合用药均明显降低α-SMA、TGF-β_1、FN蛋白表达水平。
结论:
pHGF和CTGF ASODN在离体试验和在体试验,二者均抑制肾小管上皮细胞的上皮-间质细胞转分化,抑制肾脏间质纤维化。但二者联合用药,没有协同作用。
Objective:
To explore the roles of hepatocyte growth-promoting factor(pHGF) and connective tissue growth factor(CTGF) antisense oligodeoxynucleotide(ASODN) in epithelial-to-mesenchymal transition(EMT) of human kidney epithelial cell lines(HKC) and in the process of rat renal interstitial fibrosis.
Methods:
Cell experiment:Epithelial-to-mesenchymal transition of human kidney epithelial cell lines(HKC) were induced by MCP-1 and AAⅠ,then administered pHGF,CTGF antisense oligodeoxynucleotide(ASODN) respectively and synergistically.Cell apoptosis andα-SMA mRNA were detected by flow cytometry,andα-smooth muscle actin(α-SMA) mRNA was detected by reverse transcriptase-polymerase chain reaction(RT-PCR),α-SMA,Fibronectin(FN) and transforming growth factor-β_1 (TGF-β_1) of HKC cells were assessed by indirect enzyme immunohistochemistry. Animal experiment:48 Sprague-Dawley(SD) rats were randomly divided to sham-operation group(SOR),unilateral ureteral obstruction group(UUO),pHGF treated group(pHGF),CTGF ASODN treated group,CTGF missense oligodeoxynucleotide (MSODN) treated group and Drug combination group(pHGF and CTGF ASODN).All groups of rats were treated with different drugs and raised in the following days after unilateral ureteral obstruction,then killed in the 14th day.The degree of renal fibrosis was assessed by measuring cortex hydroxyproline content, The Collagen distribution was evaluated by Masson stain,α-SMA mRNA was detected by RT-PCR,andα-SMA,FN,TGF-β_1 in the renal cortex were examined by immunohistochemistry.
Results:
Cell experiment:apoptosis rate for cells treated with 5、150、1500 ng/ml pHGF was 3.3%—4.4%on 24 h by flow cytometry,but increased to 9.1%in model group.The rate was significantly lower in treated groups than that in pHGF group(p＜0.01),but there was no difference between model group and CTGF ASODN group.The rate ofα-SMA/GAPDH in Model group,pHGF,CTGF ASODN and Drug combination group was 0.91±0.002,0.68±0.015,0.61±0.005,0.65±0.010 respectively by RT-PCR.α-SMA mRNA level in treated groups was lower than that in model group(p＜0.01). Antagonistic effect existed in pHGF and CTGF ASODN valuated by Jin Zhengjun's Q-value Probability Statistics(Q=0.572,＜0.85).Proteins ofα-SMA,FN,TGF-β_1 in HKC cells were decreased in pHGF,CTGF ASODN and combined group,detected by immunohistochemistry,compared with that in model group.
Animal experiment:Renal tissue hydroxyproline content in UUO model group, pHGF group,CTGF ASODN group,Drug combination group and CTGF MSODN group was 4.85±0.201,3.76±0.134,3.34±0.306,4.06±0.179 and 4.91±0.172μg/mg respectively.Compared wtih UUO model group,pHGF group CTGF ASODN group and Drug combination group had higher content of hydroxyproline(p＜0.01).But there was opposite effects in pHGF and CTGF ASODN valuated by Jin Zhengjun's Q-value Probability Statistics(Q =0.349,＜0.85).Fibrosis degree was weaker in pHGF group,CTGF ASODN group and Drug combination group than that in model group assessed by Masson stain.Rate ofα-SMA/β-actin mRNA in UUO group and CTGF ASODN group was 1.31±0.049,0.77±0.022 by RT-PCR,respectively.The rate in CTGF ASODN group was lower than that in UUO model group(p＜0.05),α-SMA, FN,TGF-β_1 expressed in the renal cortex were weaker in pHGF group,CTGF ASODN group and Drug combination group,compared with that in UUO model group and CTGF MSODN group detected by immunohistochemistry.
Conclusions:
pHGF and CTGF ASODN antagonize EMT of HKC and inhibited fibrosis development in rat renal interstitium induced by unilateral ureteral obstruction, respectively,but there was no synergistic effect when treated with both.
观察促肝细胞生长素(pHGF)和结缔组织生长因子(CTGF)反义寡核苷酸(ASODN)对人肾小管上皮细胞HKC上皮-间质细胞转分化,及对大鼠肾间质纤维化的作用。
方法:
细胞实验:用巨噬细胞趋化因子-1和马兜铃酸I联合用药诱导建立HKC上皮-间质细胞转分化模型。分别给与pHGF、CTGF ASODN和(pHGF+CTGF ASODN)联合用药。流式细胞仪检测12h、24h时HKC细胞凋亡率;RT-PCR方法检测α-SMA的mRNA表达水平;细胞免疫组化检测HKC细胞α-SMA、TGF-β_1、FN的蛋白表达水平。
动物实验:48只清洁级Sprague-Dawley(SD)大鼠随机分为假手术空白对照组、手术模型对照组、CTGF错义寡核苷酸对照组(CTGF MSODN)、pHGF组、CTGFASODN组、(pHGF+CTGF ASODN)联合用药组。以上各组造模后给予不同处理,饲养14d,然后处死大鼠。碱水解比色法检测新鲜湿重大鼠肾组织胶原定量;Masson染色观察肾皮质胶原形态学改变;RT-PCR检测大鼠肾组织α-SMA的mRNA表达水平;免疫组化检测大鼠肾肾皮质α-SMA、TGF-β_1、FN蛋白表达水平。
结果:
细胞试验:流式细胞仪检测:24 h模型组细胞凋亡率9.1%,浓度为15、150、1500 ng/ml的pHGF细胞凋亡率为3.3%—4.4%,与模型组比较,有显著性差异,p＜0.01;CTGF ASODN无显著差异,p＞0.05;RT-PCR方法:模型组的α-SMA/GAPDH比值为0.91±0.002,pHGF组、CTGF ASODN组和联合用药组α-SMA/GAPDH比值分别为0.68±0.015、0.61±0.005、0.65±0.010。与模型对照组比较,三者均有统计学意义,p＜0.05。但协同拮抗作用经金正均概率和法分析:Q=0.572,＜0.85,二者为拮抗作用;免疫组化检测:pHGF、CTGF ASODN和联合用药均降低α-SMA、TGF-β_1、FN蛋白水平。
动物试验:碱水解比色法:湿重肾组织胶原含量UUO模型组均值为4.85±0.201μg/mg,pHGF组均值为3.76±0.134μg/mg,CTGF ASODN组均值为3.34±0.306μg/mg,联合用药组为4.06±0.179μg/mg,CTGF MSODN错义寡核苷酸对照组为4.91±0.172。与UUO模型组比较,pHGF组、CTGF ASODN组及联合用药组均有显著性差异,p＜0.01。但协同拮抗作用,经金正均概率和法分析:pHGF和CTGF ASODN两种药物的Q=0.349,＜0.85,二者为拮抗作用;②Masson染色:与UUO模型对照组相比,pHGF、CTGF ASODN及联合用药组的肾脏着色绿染的胶原纤维面积明显减少;③RT-PCR检测:UUO模型组α-SMA/β-actin比值为1.31±0.049,CTGF ASODN组为0.77±0.022,有统计学意义,p＜0.05;④免疫组化:pHGF、CTGF ASODN及二者联合用药均明显降低α-SMA、TGF-β_1、FN蛋白表达水平。
结论:
pHGF和CTGF ASODN在离体试验和在体试验,二者均抑制肾小管上皮细胞的上皮-间质细胞转分化,抑制肾脏间质纤维化。但二者联合用药,没有协同作用。
Objective:
To explore the roles of hepatocyte growth-promoting factor(pHGF) and connective tissue growth factor(CTGF) antisense oligodeoxynucleotide(ASODN) in epithelial-to-mesenchymal transition(EMT) of human kidney epithelial cell lines(HKC) and in the process of rat renal interstitial fibrosis.
Methods:
Cell experiment:Epithelial-to-mesenchymal transition of human kidney epithelial cell lines(HKC) were induced by MCP-1 and AAⅠ,then administered pHGF,CTGF antisense oligodeoxynucleotide(ASODN) respectively and synergistically.Cell apoptosis andα-SMA mRNA were detected by flow cytometry,andα-smooth muscle actin(α-SMA) mRNA was detected by reverse transcriptase-polymerase chain reaction(RT-PCR),α-SMA,Fibronectin(FN) and transforming growth factor-β_1 (TGF-β_1) of HKC cells were assessed by indirect enzyme immunohistochemistry. Animal experiment:48 Sprague-Dawley(SD) rats were randomly divided to sham-operation group(SOR),unilateral ureteral obstruction group(UUO),pHGF treated group(pHGF),CTGF ASODN treated group,CTGF missense oligodeoxynucleotide (MSODN) treated group and Drug combination group(pHGF and CTGF ASODN).All groups of rats were treated with different drugs and raised in the following days after unilateral ureteral obstruction,then killed in the 14th day.The degree of renal fibrosis was assessed by measuring cortex hydroxyproline content, The Collagen distribution was evaluated by Masson stain,α-SMA mRNA was detected by RT-PCR,andα-SMA,FN,TGF-β_1 in the renal cortex were examined by immunohistochemistry.
Results:
Cell experiment:apoptosis rate for cells treated with 5、150、1500 ng/ml pHGF was 3.3%—4.4%on 24 h by flow cytometry,but increased to 9.1%in model group.The rate was significantly lower in treated groups than that in pHGF group(p＜0.01),but there was no difference between model group and CTGF ASODN group.The rate ofα-SMA/GAPDH in Model group,pHGF,CTGF ASODN and Drug combination group was 0.91±0.002,0.68±0.015,0.61±0.005,0.65±0.010 respectively by RT-PCR.α-SMA mRNA level in treated groups was lower than that in model group(p＜0.01). Antagonistic effect existed in pHGF and CTGF ASODN valuated by Jin Zhengjun's Q-value Probability Statistics(Q=0.572,＜0.85).Proteins ofα-SMA,FN,TGF-β_1 in HKC cells were decreased in pHGF,CTGF ASODN and combined group,detected by immunohistochemistry,compared with that in model group.
Animal experiment:Renal tissue hydroxyproline content in UUO model group, pHGF group,CTGF ASODN group,Drug combination group and CTGF MSODN group was 4.85±0.201,3.76±0.134,3.34±0.306,4.06±0.179 and 4.91±0.172μg/mg respectively.Compared wtih UUO model group,pHGF group CTGF ASODN group and Drug combination group had higher content of hydroxyproline(p＜0.01).But there was opposite effects in pHGF and CTGF ASODN valuated by Jin Zhengjun's Q-value Probability Statistics(Q =0.349,＜0.85).Fibrosis degree was weaker in pHGF group,CTGF ASODN group and Drug combination group than that in model group assessed by Masson stain.Rate ofα-SMA/β-actin mRNA in UUO group and CTGF ASODN group was 1.31±0.049,0.77±0.022 by RT-PCR,respectively.The rate in CTGF ASODN group was lower than that in UUO model group(p＜0.05),α-SMA, FN,TGF-β_1 expressed in the renal cortex were weaker in pHGF group,CTGF ASODN group and Drug combination group,compared with that in UUO model group and CTGF MSODN group detected by immunohistochemistry.
Conclusions:
pHGF and CTGF ASODN antagonize EMT of HKC and inhibited fibrosis development in rat renal interstitium induced by unilateral ureteral obstruction, respectively,but there was no synergistic effect when treated with both.
引文
[1]李玉林,叶诸榕,龚守良,文剑明,李一雷,李才,吕申,杨向红.分子病理学,人民卫生出版社;2002(8) 1,240-261.
[2]Bohle A,MUller GA,Wehrmann M,Mackensen-Haen S,Xiao JC.Pathogenesis of chronic renal failure in the primary glmerulopathies,renal vasculopathies,and chronic interstitial nephritides[J].Kidney Int,1996,49(Supp154):S2-S9.
[3]Meguid El Nahas A,Bello AK.Chronic kidney disease:the global challenge[J].Lancet.2005,365(9456):331-340.
[4]Nishida M,Fujinaka H,Matsusaka T,et al.Absence of angiotensin Ⅱ type Ⅰreceptor in bone marrow-derived cells is detrimental in the evolution of renal fibrosis[J].J Clin Invest.2002,110(12):1859-1868.
[5]Eddy AA.Progression in chronic kidney disease[J].Adv Chronic Kidney Dis.2005,12(4):353-365.
[6]Junwei Yang,Ryan W.Shultz,Wendy M.Mars,Rodney E.Wegner,Yingiian Li,Chunsun Dai,Kari Nejak,and Youhua Liu.Disruption of tissue-type plasminogen activator gene in mice reduces renal interstitial fibrosis in obstructive nephropathy[J].J Clin Invest.2002,110(10):1525-1538.
[7]Strutz F.Novel aspects of renal fibrogenesis[J].Nephrol Dial Transplant.1995,10(9):1526-1532.
[8]Fan JM,Ng YY,Hill PA,et al.Transforming growth factor-beta regulates tubular epithelial-myofibroblast transdifferentiation in vitro[J].Kidney Int.1999,56(4):1455-1467.
[9]Iwano M,Plieth D,DanoffTM,Xue C,Okada H,Neilson EG.Evidence that fibroblasts derive from epithelium during tissue fibrosis[J].J Clin Invest,2002,110(3):341-350.
[10]Yang J,Liu Y.Dissection of Key Events in Tubular Epithelial to Myofibroblast Transition and Its Implications in Renal Interstitial Fibrosis[J].Am J Pathol,2001;159(4):1465-1475.
[11]Zeisberg M,Hanai J,Sugimoto H,Mammoto T,Charytan D,Strutz F,Kalluri R..BMP7 counteracts TGF-betal-induced epithelial-to-mesenchymal transition and reverses chronic renal injury[J].Nat Med.2003,9(7):964-968.
[12]Thiery JP,Sleeman JP.Complex networks orchestrate epithelial-mesenchymal transitions[J].Nat Rev Mol Cell Biol. 2006,7(2):131-142.
[13] Gauldie J, Bonniaud P, Sime P, Ask K, Kolb M. TGF-beta, Smad3 and the process of progressive fibrosis[J]. Biochem Soc Trans. 2007, 35(Pt 4):661-664.
[14] Li Y, Yang J, Dai C, Wu C, Liu Y. Role for integrin-linked kinase in mediating tubular epithelial to mesenchymal transition and renal interstitial fibrogenesis[ J ]. J Clin Invest., 2003,112 (4):503-516.
[15] B Stemmer V, de Craene B, Berx G, Behrens J. Snail promotes Wnt target gene expression and interacts with beta-catenin[J]. Oncogene. 2008, 14(11): 1034-10399.
[16] Barasch J, Yang J, Ware CB, Taga T, Yoshida K, Erdjument-Bromage H, Tempst P, Parravicini E, Malach S, Aranoff T, Oliver JA. Mesenchymal to epithelial conversion in rat metanephros is induced by LIF[J]. Cell. 1999, 99(4):377-386.
[17] Zeisberg M, Hanai J, Sugimoto H, Mammoto T, Charytan D, Strutz F, Kalluri R. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury[J]. Nat Med. 2003,9(7):964-968.
[18] Massague J. How cells read TGF-beta signals[J]. Nat Rev Mol Cell Biol. 2000, 1(3): 169-78.
[19] Forino M, Torregrossa R, Ceol M, Murer L, Vella MD, Prete DD, D'Angelo A, Anglani F. TGFbetal induces epithelial-mesenchymal transition, but not myofibroblast transdifferentiation of human kidney tubular epithelial cells in primary culture[J]. Int J Exp Pathol. 2006, 87(3): 197-208.
[20] Roberts AB, Tian F, Byfield SD, Sruelten C, Ooshima A, Saika S, Flanders KC. Smad3 is key to TGF-beta-mediated epithelial-to-mesenchymal transition, fibrosis, tumor suppression and metastasis[J]. Cytokine Growth Factor Rev 2006, 17(1-2): 19-27.
[21] Rhyu DY, Yang Y, Ha H, Lee GT, Song JS, Uh ST, Lee HB. Role of reactive oxygen species in TGF-beta1-induced mitogen-activated protein kinase activation and epithelial-mesenchymal transition in renal tubular epithelial cells[J]. J Am Soc Nephrol,2005, 16(3):667-675.
[22] Strutz F, Zeisberg M, Renziehausen A, Raschke B, Becker V, van Kooten C, Muller G.TGF-β_1 induces proliferation in human renal fibroblasts via induction of basic fibroblast growth[J]. Kidney Int. 2001, 59(2):579-592.
[23] Choi ME. Mechanism of transforming growth factor-beta1 signaling: [J]. Kidney Int. 2000, 58(suppl 77):S53-S58.
[24] Cravedi P, Ruggenenti P, Remuzzi G. Does remission of renal disease associated with antihypertensive treatment exist?[J].Curr Hypertens Rep.2007,9(2):160-165.
[25]Baum B,Settleman J,Quinlan MP.Transitions between epithelial and mesenchymal states in development and disease[J].Semin Cell Dev Biol.2008,19(3):294-308.
[26]Satoh M,Kashihara N,Yamasaki Y,Maruyama K,Okamoto K,Maeshima Y,Sugiyama H,Sugaya T,Murakami K,Makino H.Renal interstitial fibrosis is reduced in angiotensin Ⅱ type la receptor-deficient mice[J].J Am Soc Nephrol.2001,12(2):317-25.
[27]Basile DP.Is angiotensin Ⅱ's role in fibrosis as easy as PAI(-1)?[J].Kidney Int.2000,8(1):460-461.
[28]Weigert C,Brodbeck K,Klopfer K,Haring HU,Schleicher ED.Angiotensin Ⅱ induces human TGF-beta 1 promoter activation:similarity to hyperglycaemia[J].Diabetologia.2002,45(6):890-898.
[29]Abuissa H,O'Keefe J Jr.The role of renin-angiotensin-aldosterone system-based therapy in diabetes prevention and cardiovascular and renal protection[J].Diabetes Obes Metab.2008,18(6):1460-1468.
[30]Yoshiji H,Kuriyama S,Fukui H.Blockade of renin-angiotensin system in antifibrotic therapy[J].J Gastroenterol Hepatol.2007,22(Suppl 1):S593-S595.
[31]Liu Y.Renal fibrosis:new insights into the pathogenesis and therapeutics[J].Kidney Int.2006,69(2):213-217.
[32]万青松,夏明珠,胡家.肾间质纤维化的分子基础[J].中国中西医结合肾病杂志.2003,4(7):429-430.
[33]Nakamura T,Nawa K,Ichihara A.Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats[J].Biochem Biophys Res Commun.1984,16;122(3):1450-1459.
[34]Liu Y,Yang J.Hepatocyte growth factor:new arsenal in the fights against renal fibrosis?[J].Kidney Int.2006,70(2):238-240.
[35]Mizuno S,Matsumoto K,Kurosawa T,Mizuno-Horikawa Y,Nakamura T.Reciprocal balance of hepatocyte growth factor and transforming growth factor-beta 1 in renal fibrosis in mice[J].Kidney Int.2000,57(3):937-948.
[36]Yazawa K,Isaka Y,Takahara S,Imai E,Ichimaru N,Shi Y,Namba Y,Okuyama A.Direct transfer of hepatocyte growth factor gene into kidney suppresses cyclosporin a nephrotoxicity in rats[J].Nephrol Dial Transplant. 2004, 19(4):812-816.
[37] Yang J, Liu Y. Delayed administration of hepatocyte growth factor reduces renal fibrosis in obstructive nephropathy. [J]. Am J Physiol Renal Physiol. 2003, 284(2):F349-F357.
[38] Tanaka T, Ichimaru N, Takahara S, Yazawa K, Hatori M, Suzuki K, Isaka Y, Moriyama T, Imai E, Azuma H, Nakamura T, Okuyama A, Yamanaka H. In vivo gene transfer of hepatocyte growth factor to skeletal muscle prevents changes in rat kidneys after 5/6 nephrectomy[J]. Am J Transplant. 2002, 2(9):828-836
[39] Mizuno S, Matsumoto K, Nakamura T. Hepatocyte growth factor suppresses interstitial fibrosis in a mouse model of obstructive nephropathy[J]. Kidney Int. 2001, 59(4): 1304-1314.
[40] Uehara Y, Minowa O, Mori C, Shiota K, Kuno J, Noda T, Kitamura N. Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor[J].Nature. 1995, 373(6516):702-705.
[41] Karihaloo A, Kale S, Rosenblum ND, Cantley LG. Hepatocyte growth factor-mediated renal epithelial branching morphogenesis is regulated by glypican-4 expression[J]. Mol Cell Biol. 2004, 24(19):8745-8752.
[42] Mazzaferro S. Is there any role predictable for bone morphogenetic protein-7 in nephrology? [J]. G Ital Nefrol. 2006, 23(2): 129-137.
[43] Urist MR.Bone formation by autoinduction[J]. Science ,1965 ,150 (6): 893- 895.
[44] Simic P ,Vukicevic S.Bone morphogenetic Proteins in development and homeostasis of kidney[J].Cytokine Growth Factor Rev ,2005 ,16 (3) :299-30 8.
[45] Li T, Surendran K, Zawaideh MA, Mathew S, Hruska KA. Bone morphogenetic protein 7: a novel treatment for chronic renal and bone disease[J].Curr Opin Nephrol Hypertens. 2004, 13(4):417-422.
[46] Li T, Surendran K, Zawaideh MA, Mathew S, Hruska KA. Bone morphogenetic protein 7: a novel treatment for chronic renal and bone disease[J].Curr Opin Nephrol Hypertens. 2004, 3(4):417-422.
[47] Wang SE, Wu FY, Shin I, Qu S, Arteaga CL. Transforming growth factor {beta} (TGF-{beta})-Smad target gene protein tyrosine phosphatase receptor type kappa is required for TGF-{beta} function[J].Mol Cell Biol. 2005 , 25(11):4703-4715.
[48] Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics[J]. Kidney Int. 2006, 69(2):213-217.
[49] Labrecque DR. Hepatic stimulator substance:discover, characteristis and mechanism of action[J]. Dig Dis Sci, 1991, 36 (5):669-673.
[50] 张宜俊,孔祥平,郑国池,等. Evaluation of Hepatocyte Growth-promoting factors in treating 1687 cases of fulminant hepatitis[J]. Chin Med, 1995,108(12):928-929.
[51]张宜俊.促肝细胞生长素近年来研究进展[J].中西医结合肝病杂志,1998,8(增刊):13-16.
[52]Funakoshi Hiroshi,Nakamura Toshikazu.Hepatocyte growth factor:from diagnosis to clinical applications[J].Clinica Chimica Acta,2003,327(1-2):1- 23.
[53]Liu You-hua.Hepatocyte growth factor in kidney fibrosis:therapeutic potential and mechanisms of action[J].Am J Physiol Renal Physiol,2004,287(1):F7 - F16.
[54]Sato S,Dai W,Liu XL,Asano G.The protective effect of hepatocyte growth-promoting factor(pHGF) against carbon tetrachloride-induced acute liver injury in rats:an ultrastructural study[J].Med Electron Microsc.1999,32(3):184-192.
[55]Liu Xiao-Lan,Sato Shigeru,Dai Wei.The protective effect of hepatocyte growth-promoting factor(pHGF) against hydrogen peroxide-induced acute lung injury in rats[J].Med Electron Microsc,2001,34(2):92-102.
[56]Liao J,Tang W,Wang J,Zhang W.Effects of pHGF on renal cellular DNA synthesis after partial hepatectomy in rats[J].J Tongji Med Univ.2000;20(1):55-6.
[57]薛痕,樊均明,陈亮,李孜,胡章学,刘先蓉.肝细胞生长因子负性调控细胞转分化在肾间质纤维化中的作用[J].中华肾脏病杂志,2005,21(8):458-463.
[58]刘欣颖,罗海,王宓,陈辉珍,苏白海,李孜,许国章,樊均明.肝细胞生长因子对IL-1A刺激。肾小管上皮细胞肌纤维母细胞转分化的作用[J].四川大学学报(医学版),2005,36(1):9-12.
[59]岳屹囡,蒋红雨.促肝细胞生长素对肾缺血-再灌注损伤大鼠NO及肾脏病理学的影响fJl.济宁医学院学报,2006,29(4):15-18.
[60]Rajeswari J,Pande G.The significance of alpha 5 beta 1 integrin dependent and independent actin cytoskelton organization in cell transformati and survival[J]Cell Biol Int.2002,26(12):1043-55.
[61]Eddy AA.Plasminogen activator inhibitor-1 and the kidney[J].Am J Physiol Renal Physiol.2002,283(2):F209-F220.
[62]Rerolle JP,Hertig A,Nguyen G,Sraer JD,Rondeau EP.Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis[J].Kidney Int.2000,58(5):1841-1850.
[63]Chen RQ,Chen XM,Cui SW,Cai GY,Shi SZ,Xie YS,Lu Y,Peng LX.Significance of imbalance between matrix metalloproteinases and tissue type inhibitor of metalloproteinases in renal tubulointerstitial lesions of aging rats[J].Zhonghua Yi Xue Za Zhi.2004,84(11):937-942.
[64]Wagner R W.Gene inhibition using antisense oligodeoxynucleotides[J].Nature,1994,372(6504):333-335.
[65]Reynods T.First antisense drug trials planned in leukemia[J].J Natl Cancer Inst,1992,84:288-291.
[66]van der Wouden EA,Sandovici M,Henning RH,de Zeeuw D,Deelman LE.Approaches and methods in gene therapy for kidney disease[J].J Pharmaeol Toxicol Methods.2004,50(1):13-24.
[67]Sharma K,Jin Y,Guo J,Ziyadeh FN.Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice[J].Diabetes,1996,45(4):522-530.
[68]Qi W,Chen X,Poronnik P,Pollock CA.Transforming growth factor-betal differentially mediates fibronectin and inflammatory cytokine expression in kidney tubular cells[J].Am J Physiol Renal Physiol,2006,291(5):F1070 -F1077.
[69]Bottinger EP,Letterio JJ,Roberts AB.Biology of TGF-beta in knockout and transgenic mouse models[J].Kidney Int.1997,51(5),1355-1360.
[70]Qi W,Chen X,Poronnik P,Pollock CA.Transforming growth factor- β/connective tissue growth factor axis in the kidney[J].Int J Biochem Cell Biol,2008,40(1):9-13.
[71]Qi W,Chen X,Poronnik P,Pollock CA..The renal cortical fibroblast in renal tubulointerstitial fibrosis[J].Int J Biochem Cell Biol,2006,38(1):1-5.
[72]Qi W,Chen X,Poronnik P,Pollock CA.TGF-betal induces IL-8 and MCP-1through a connective tissue growth factor-independent pathway[J].Am J Physiol Renal Physiol.2006,290(3):F70-F709.
[73]Yokoi H,Mukoyama M,Nagae T,Mori K,Suganami T,Sawai K,Yoshioka T,Koshikawa M,Nishida T,Takigawa M,Sugawara A,Nakao K.Reduction in connective tissue growth factor by antisense treatment ameliorates renal tubulointerstitial fibrosis[J].J Am Soc Nephrol.2004,15(6):1430-1440.
[74]Guha M,Xu ZG,Tung D,Lanting L,Natarajan R.Specific down-regulation of connective tissue growth factor attenuates progression of nephropathy in mouse models of type 1 and type 2 diabetes[J].FASEB J.2007,21(12):3355-3368.
[75]沙文刚,樊均明.CTGF反义寡核苷酸对肾小管上皮细胞胶原Ⅲ分泌的影响[J].苏州大学学报(医学版),2005,25(6):1023-1025.
[76]陈珑,刘必成,马坤岭,刘宏,罗冬冬.CTGF反义寡核苷酸对AngⅡ诱导的人近曲肾小管上皮细胞转分化的影响[J].东南大学学报(医学版).2006,25(3):168-173.
[77]Godbey WT,Wu KK,Mikos AG.Poly(ethylenimine) and its role in gene delivery[J].J.Controlled Release,1999,60:149-160.
[78]Suh J,Paik HJ,Hwang BK.Ionization of polyethylenimine and polyallylamine at various pHs[J].Bioorg.Chem.,1994,22:318-327.
[79]Tang MX,Szoka FC.The influence of polymer structure upon the interactions of cationic polymers with DNA and morphology of the resulting complex[J].Gene Ther,1997,4:823-832.
[80]Ferrari S,Pettenazzo A,Garbati N,Zacchello F,Behr JP,Scarpa M.Polyethylenimine shows properties of interest for cystic fibrosis gene therapy[J].Biochim Biophys Acta,1999,1447(23):219-225.
[81]Leonetti JP,Degols G,Lebleu B.Biological activity of oligonucleotide-poly(L-lysine) conjugates:mechanism of cell uptake[J]. Bioconjug.Chem,1990,1(2):149-153.
[82]郑法雷,文晓彦,李雪,高瑞通,张晓明.单个核细胞趋化蛋白-1和马兜铃酸Ⅰ在诱导人类肾小管上皮细胞转分化中的协同作用[J].中华内科杂志2000,39(12):831-834.
[83]郭 华,邹万忠.肾小管间质纤维化实验动物模型的制备方法[J].临床与实验病理学杂志2003,19(2):211-212.
[84]王芳,蒋建伟,陈涛,曹明溶.聚乙烯亚胺介导生存素反义核酸体外投递肝癌SMMC-7721细胞的条件优化[J].暨南大学学报(自然科学与医学版),2006,27(4):551-556.
[85]金正均.合并用药中的相加[J].中国药理学报,1980,1(2):70-76.
[2]Bohle A,MUller GA,Wehrmann M,Mackensen-Haen S,Xiao JC.Pathogenesis of chronic renal failure in the primary glmerulopathies,renal vasculopathies,and chronic interstitial nephritides[J].Kidney Int,1996,49(Supp154):S2-S9.
[3]Meguid El Nahas A,Bello AK.Chronic kidney disease:the global challenge[J].Lancet.2005,365(9456):331-340.
[4]Nishida M,Fujinaka H,Matsusaka T,et al.Absence of angiotensin Ⅱ type Ⅰreceptor in bone marrow-derived cells is detrimental in the evolution of renal fibrosis[J].J Clin Invest.2002,110(12):1859-1868.
[5]Eddy AA.Progression in chronic kidney disease[J].Adv Chronic Kidney Dis.2005,12(4):353-365.
[6]Junwei Yang,Ryan W.Shultz,Wendy M.Mars,Rodney E.Wegner,Yingiian Li,Chunsun Dai,Kari Nejak,and Youhua Liu.Disruption of tissue-type plasminogen activator gene in mice reduces renal interstitial fibrosis in obstructive nephropathy[J].J Clin Invest.2002,110(10):1525-1538.
[7]Strutz F.Novel aspects of renal fibrogenesis[J].Nephrol Dial Transplant.1995,10(9):1526-1532.
[8]Fan JM,Ng YY,Hill PA,et al.Transforming growth factor-beta regulates tubular epithelial-myofibroblast transdifferentiation in vitro[J].Kidney Int.1999,56(4):1455-1467.
[9]Iwano M,Plieth D,DanoffTM,Xue C,Okada H,Neilson EG.Evidence that fibroblasts derive from epithelium during tissue fibrosis[J].J Clin Invest,2002,110(3):341-350.
[10]Yang J,Liu Y.Dissection of Key Events in Tubular Epithelial to Myofibroblast Transition and Its Implications in Renal Interstitial Fibrosis[J].Am J Pathol,2001;159(4):1465-1475.
[11]Zeisberg M,Hanai J,Sugimoto H,Mammoto T,Charytan D,Strutz F,Kalluri R..BMP7 counteracts TGF-betal-induced epithelial-to-mesenchymal transition and reverses chronic renal injury[J].Nat Med.2003,9(7):964-968.
[12]Thiery JP,Sleeman JP.Complex networks orchestrate epithelial-mesenchymal transitions[J].Nat Rev Mol Cell Biol. 2006,7(2):131-142.
[13] Gauldie J, Bonniaud P, Sime P, Ask K, Kolb M. TGF-beta, Smad3 and the process of progressive fibrosis[J]. Biochem Soc Trans. 2007, 35(Pt 4):661-664.
[14] Li Y, Yang J, Dai C, Wu C, Liu Y. Role for integrin-linked kinase in mediating tubular epithelial to mesenchymal transition and renal interstitial fibrogenesis[ J ]. J Clin Invest., 2003,112 (4):503-516.
[15] B Stemmer V, de Craene B, Berx G, Behrens J. Snail promotes Wnt target gene expression and interacts with beta-catenin[J]. Oncogene. 2008, 14(11): 1034-10399.
[16] Barasch J, Yang J, Ware CB, Taga T, Yoshida K, Erdjument-Bromage H, Tempst P, Parravicini E, Malach S, Aranoff T, Oliver JA. Mesenchymal to epithelial conversion in rat metanephros is induced by LIF[J]. Cell. 1999, 99(4):377-386.
[17] Zeisberg M, Hanai J, Sugimoto H, Mammoto T, Charytan D, Strutz F, Kalluri R. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury[J]. Nat Med. 2003,9(7):964-968.
[18] Massague J. How cells read TGF-beta signals[J]. Nat Rev Mol Cell Biol. 2000, 1(3): 169-78.
[19] Forino M, Torregrossa R, Ceol M, Murer L, Vella MD, Prete DD, D'Angelo A, Anglani F. TGFbetal induces epithelial-mesenchymal transition, but not myofibroblast transdifferentiation of human kidney tubular epithelial cells in primary culture[J]. Int J Exp Pathol. 2006, 87(3): 197-208.
[20] Roberts AB, Tian F, Byfield SD, Sruelten C, Ooshima A, Saika S, Flanders KC. Smad3 is key to TGF-beta-mediated epithelial-to-mesenchymal transition, fibrosis, tumor suppression and metastasis[J]. Cytokine Growth Factor Rev 2006, 17(1-2): 19-27.
[21] Rhyu DY, Yang Y, Ha H, Lee GT, Song JS, Uh ST, Lee HB. Role of reactive oxygen species in TGF-beta1-induced mitogen-activated protein kinase activation and epithelial-mesenchymal transition in renal tubular epithelial cells[J]. J Am Soc Nephrol,2005, 16(3):667-675.
[22] Strutz F, Zeisberg M, Renziehausen A, Raschke B, Becker V, van Kooten C, Muller G.TGF-β_1 induces proliferation in human renal fibroblasts via induction of basic fibroblast growth[J]. Kidney Int. 2001, 59(2):579-592.
[23] Choi ME. Mechanism of transforming growth factor-beta1 signaling: [J]. Kidney Int. 2000, 58(suppl 77):S53-S58.
[24] Cravedi P, Ruggenenti P, Remuzzi G. Does remission of renal disease associated with antihypertensive treatment exist?[J].Curr Hypertens Rep.2007,9(2):160-165.
[25]Baum B,Settleman J,Quinlan MP.Transitions between epithelial and mesenchymal states in development and disease[J].Semin Cell Dev Biol.2008,19(3):294-308.
[26]Satoh M,Kashihara N,Yamasaki Y,Maruyama K,Okamoto K,Maeshima Y,Sugiyama H,Sugaya T,Murakami K,Makino H.Renal interstitial fibrosis is reduced in angiotensin Ⅱ type la receptor-deficient mice[J].J Am Soc Nephrol.2001,12(2):317-25.
[27]Basile DP.Is angiotensin Ⅱ's role in fibrosis as easy as PAI(-1)?[J].Kidney Int.2000,8(1):460-461.
[28]Weigert C,Brodbeck K,Klopfer K,Haring HU,Schleicher ED.Angiotensin Ⅱ induces human TGF-beta 1 promoter activation:similarity to hyperglycaemia[J].Diabetologia.2002,45(6):890-898.
[29]Abuissa H,O'Keefe J Jr.The role of renin-angiotensin-aldosterone system-based therapy in diabetes prevention and cardiovascular and renal protection[J].Diabetes Obes Metab.2008,18(6):1460-1468.
[30]Yoshiji H,Kuriyama S,Fukui H.Blockade of renin-angiotensin system in antifibrotic therapy[J].J Gastroenterol Hepatol.2007,22(Suppl 1):S593-S595.
[31]Liu Y.Renal fibrosis:new insights into the pathogenesis and therapeutics[J].Kidney Int.2006,69(2):213-217.
[32]万青松,夏明珠,胡家.肾间质纤维化的分子基础[J].中国中西医结合肾病杂志.2003,4(7):429-430.
[33]Nakamura T,Nawa K,Ichihara A.Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats[J].Biochem Biophys Res Commun.1984,16;122(3):1450-1459.
[34]Liu Y,Yang J.Hepatocyte growth factor:new arsenal in the fights against renal fibrosis?[J].Kidney Int.2006,70(2):238-240.
[35]Mizuno S,Matsumoto K,Kurosawa T,Mizuno-Horikawa Y,Nakamura T.Reciprocal balance of hepatocyte growth factor and transforming growth factor-beta 1 in renal fibrosis in mice[J].Kidney Int.2000,57(3):937-948.
[36]Yazawa K,Isaka Y,Takahara S,Imai E,Ichimaru N,Shi Y,Namba Y,Okuyama A.Direct transfer of hepatocyte growth factor gene into kidney suppresses cyclosporin a nephrotoxicity in rats[J].Nephrol Dial Transplant. 2004, 19(4):812-816.
[37] Yang J, Liu Y. Delayed administration of hepatocyte growth factor reduces renal fibrosis in obstructive nephropathy. [J]. Am J Physiol Renal Physiol. 2003, 284(2):F349-F357.
[38] Tanaka T, Ichimaru N, Takahara S, Yazawa K, Hatori M, Suzuki K, Isaka Y, Moriyama T, Imai E, Azuma H, Nakamura T, Okuyama A, Yamanaka H. In vivo gene transfer of hepatocyte growth factor to skeletal muscle prevents changes in rat kidneys after 5/6 nephrectomy[J]. Am J Transplant. 2002, 2(9):828-836
[39] Mizuno S, Matsumoto K, Nakamura T. Hepatocyte growth factor suppresses interstitial fibrosis in a mouse model of obstructive nephropathy[J]. Kidney Int. 2001, 59(4): 1304-1314.
[40] Uehara Y, Minowa O, Mori C, Shiota K, Kuno J, Noda T, Kitamura N. Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor[J].Nature. 1995, 373(6516):702-705.
[41] Karihaloo A, Kale S, Rosenblum ND, Cantley LG. Hepatocyte growth factor-mediated renal epithelial branching morphogenesis is regulated by glypican-4 expression[J]. Mol Cell Biol. 2004, 24(19):8745-8752.
[42] Mazzaferro S. Is there any role predictable for bone morphogenetic protein-7 in nephrology? [J]. G Ital Nefrol. 2006, 23(2): 129-137.
[43] Urist MR.Bone formation by autoinduction[J]. Science ,1965 ,150 (6): 893- 895.
[44] Simic P ,Vukicevic S.Bone morphogenetic Proteins in development and homeostasis of kidney[J].Cytokine Growth Factor Rev ,2005 ,16 (3) :299-30 8.
[45] Li T, Surendran K, Zawaideh MA, Mathew S, Hruska KA. Bone morphogenetic protein 7: a novel treatment for chronic renal and bone disease[J].Curr Opin Nephrol Hypertens. 2004, 13(4):417-422.
[46] Li T, Surendran K, Zawaideh MA, Mathew S, Hruska KA. Bone morphogenetic protein 7: a novel treatment for chronic renal and bone disease[J].Curr Opin Nephrol Hypertens. 2004, 3(4):417-422.
[47] Wang SE, Wu FY, Shin I, Qu S, Arteaga CL. Transforming growth factor {beta} (TGF-{beta})-Smad target gene protein tyrosine phosphatase receptor type kappa is required for TGF-{beta} function[J].Mol Cell Biol. 2005 , 25(11):4703-4715.
[48] Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics[J]. Kidney Int. 2006, 69(2):213-217.
[49] Labrecque DR. Hepatic stimulator substance:discover, characteristis and mechanism of action[J]. Dig Dis Sci, 1991, 36 (5):669-673.
[50] 张宜俊,孔祥平,郑国池,等. Evaluation of Hepatocyte Growth-promoting factors in treating 1687 cases of fulminant hepatitis[J]. Chin Med, 1995,108(12):928-929.
[51]张宜俊.促肝细胞生长素近年来研究进展[J].中西医结合肝病杂志,1998,8(增刊):13-16.
[52]Funakoshi Hiroshi,Nakamura Toshikazu.Hepatocyte growth factor:from diagnosis to clinical applications[J].Clinica Chimica Acta,2003,327(1-2):1- 23.
[53]Liu You-hua.Hepatocyte growth factor in kidney fibrosis:therapeutic potential and mechanisms of action[J].Am J Physiol Renal Physiol,2004,287(1):F7 - F16.
[54]Sato S,Dai W,Liu XL,Asano G.The protective effect of hepatocyte growth-promoting factor(pHGF) against carbon tetrachloride-induced acute liver injury in rats:an ultrastructural study[J].Med Electron Microsc.1999,32(3):184-192.
[55]Liu Xiao-Lan,Sato Shigeru,Dai Wei.The protective effect of hepatocyte growth-promoting factor(pHGF) against hydrogen peroxide-induced acute lung injury in rats[J].Med Electron Microsc,2001,34(2):92-102.
[56]Liao J,Tang W,Wang J,Zhang W.Effects of pHGF on renal cellular DNA synthesis after partial hepatectomy in rats[J].J Tongji Med Univ.2000;20(1):55-6.
[57]薛痕,樊均明,陈亮,李孜,胡章学,刘先蓉.肝细胞生长因子负性调控细胞转分化在肾间质纤维化中的作用[J].中华肾脏病杂志,2005,21(8):458-463.
[58]刘欣颖,罗海,王宓,陈辉珍,苏白海,李孜,许国章,樊均明.肝细胞生长因子对IL-1A刺激。肾小管上皮细胞肌纤维母细胞转分化的作用[J].四川大学学报(医学版),2005,36(1):9-12.
[59]岳屹囡,蒋红雨.促肝细胞生长素对肾缺血-再灌注损伤大鼠NO及肾脏病理学的影响fJl.济宁医学院学报,2006,29(4):15-18.
[60]Rajeswari J,Pande G.The significance of alpha 5 beta 1 integrin dependent and independent actin cytoskelton organization in cell transformati and survival[J]Cell Biol Int.2002,26(12):1043-55.
[61]Eddy AA.Plasminogen activator inhibitor-1 and the kidney[J].Am J Physiol Renal Physiol.2002,283(2):F209-F220.
[62]Rerolle JP,Hertig A,Nguyen G,Sraer JD,Rondeau EP.Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis[J].Kidney Int.2000,58(5):1841-1850.
[63]Chen RQ,Chen XM,Cui SW,Cai GY,Shi SZ,Xie YS,Lu Y,Peng LX.Significance of imbalance between matrix metalloproteinases and tissue type inhibitor of metalloproteinases in renal tubulointerstitial lesions of aging rats[J].Zhonghua Yi Xue Za Zhi.2004,84(11):937-942.
[64]Wagner R W.Gene inhibition using antisense oligodeoxynucleotides[J].Nature,1994,372(6504):333-335.
[65]Reynods T.First antisense drug trials planned in leukemia[J].J Natl Cancer Inst,1992,84:288-291.
[66]van der Wouden EA,Sandovici M,Henning RH,de Zeeuw D,Deelman LE.Approaches and methods in gene therapy for kidney disease[J].J Pharmaeol Toxicol Methods.2004,50(1):13-24.
[67]Sharma K,Jin Y,Guo J,Ziyadeh FN.Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice[J].Diabetes,1996,45(4):522-530.
[68]Qi W,Chen X,Poronnik P,Pollock CA.Transforming growth factor-betal differentially mediates fibronectin and inflammatory cytokine expression in kidney tubular cells[J].Am J Physiol Renal Physiol,2006,291(5):F1070 -F1077.
[69]Bottinger EP,Letterio JJ,Roberts AB.Biology of TGF-beta in knockout and transgenic mouse models[J].Kidney Int.1997,51(5),1355-1360.
[70]Qi W,Chen X,Poronnik P,Pollock CA.Transforming growth factor- β/connective tissue growth factor axis in the kidney[J].Int J Biochem Cell Biol,2008,40(1):9-13.
[71]Qi W,Chen X,Poronnik P,Pollock CA..The renal cortical fibroblast in renal tubulointerstitial fibrosis[J].Int J Biochem Cell Biol,2006,38(1):1-5.
[72]Qi W,Chen X,Poronnik P,Pollock CA.TGF-betal induces IL-8 and MCP-1through a connective tissue growth factor-independent pathway[J].Am J Physiol Renal Physiol.2006,290(3):F70-F709.
[73]Yokoi H,Mukoyama M,Nagae T,Mori K,Suganami T,Sawai K,Yoshioka T,Koshikawa M,Nishida T,Takigawa M,Sugawara A,Nakao K.Reduction in connective tissue growth factor by antisense treatment ameliorates renal tubulointerstitial fibrosis[J].J Am Soc Nephrol.2004,15(6):1430-1440.
[74]Guha M,Xu ZG,Tung D,Lanting L,Natarajan R.Specific down-regulation of connective tissue growth factor attenuates progression of nephropathy in mouse models of type 1 and type 2 diabetes[J].FASEB J.2007,21(12):3355-3368.
[75]沙文刚,樊均明.CTGF反义寡核苷酸对肾小管上皮细胞胶原Ⅲ分泌的影响[J].苏州大学学报(医学版),2005,25(6):1023-1025.
[76]陈珑,刘必成,马坤岭,刘宏,罗冬冬.CTGF反义寡核苷酸对AngⅡ诱导的人近曲肾小管上皮细胞转分化的影响[J].东南大学学报(医学版).2006,25(3):168-173.
[77]Godbey WT,Wu KK,Mikos AG.Poly(ethylenimine) and its role in gene delivery[J].J.Controlled Release,1999,60:149-160.
[78]Suh J,Paik HJ,Hwang BK.Ionization of polyethylenimine and polyallylamine at various pHs[J].Bioorg.Chem.,1994,22:318-327.
[79]Tang MX,Szoka FC.The influence of polymer structure upon the interactions of cationic polymers with DNA and morphology of the resulting complex[J].Gene Ther,1997,4:823-832.
[80]Ferrari S,Pettenazzo A,Garbati N,Zacchello F,Behr JP,Scarpa M.Polyethylenimine shows properties of interest for cystic fibrosis gene therapy[J].Biochim Biophys Acta,1999,1447(23):219-225.
[81]Leonetti JP,Degols G,Lebleu B.Biological activity of oligonucleotide-poly(L-lysine) conjugates:mechanism of cell uptake[J]. Bioconjug.Chem,1990,1(2):149-153.
[82]郑法雷,文晓彦,李雪,高瑞通,张晓明.单个核细胞趋化蛋白-1和马兜铃酸Ⅰ在诱导人类肾小管上皮细胞转分化中的协同作用[J].中华内科杂志2000,39(12):831-834.
[83]郭 华,邹万忠.肾小管间质纤维化实验动物模型的制备方法[J].临床与实验病理学杂志2003,19(2):211-212.
[84]王芳,蒋建伟,陈涛,曹明溶.聚乙烯亚胺介导生存素反义核酸体外投递肝癌SMMC-7721细胞的条件优化[J].暨南大学学报(自然科学与医学版),2006,27(4):551-556.
[85]金正均.合并用药中的相加[J].中国药理学报,1980,1(2):70-76.